Ou, I agree with you except it is for Sapacitabine and it may be more near term than imagined. Remember, the article and press release is about a drug on phase 3 trials for AML and soon to he in phase 3 trial for MDS. If I heard correctly, an article on Sapacitabine and the HR DNA repair pathway will be published shortly and a press release will be issued.
There is an amazing trial underway called the ISpy2 trial for breast cancer that is utilizing at least 5 experimental drugs from various bio pharmaceutical companies at different test centers through out the USA . The trials are designed to shorten the time between discovery of the drug and the time it takes to bit the market. If Sapacitabine were included in the trial, I think it would be very positive in terms of credibility for Sapacitabines use in solid tumors where there has been impairment of the HR DNA repair pathway such as triple negative breast and ovarian cancer.
I am also intrigued by publication possibilites. Is the article about Sapacitabine going to be published in the New England Journal of Medicine? If it is, look for a huge pop in the share price.
In any event, only 57 days until the ASH conference and the release of Sapacitabine phase 2 data for MDS!